<DOC>
	<DOCNO>NCT00063778</DOCNO>
	<brief_summary>The purpose study see different dos experimental HIV vaccine safe study immune system respond vaccine . The vaccine test healthy , HIV uninfected volunteer . AVX101 contain one many substance HIV need make copy ; therefore , vaccine cause HIV AIDS .</brief_summary>
	<brief_title>Safety HIV Vaccine ( AVX101 ) HIV Uninfected Volunteers United States South Africa</brief_title>
	<detailed_description>This study design evaluate safety immunogenicity alphavirus replicon HIV subtype C gag vaccine . This vaccine utilize propagation-defective replicon vector system derive attenuated strain Venezuelan Equine Encephalitis ( VEE ) virus . The vaccine replicon express gag gene South African subtype C isolate HIV-1 . This study evaluate AVX101 vaccine healthy , HIV uninfected volunteer United States South Africa . Participants randomize receive either vaccine placebo study entry Months 1 3 . The study originally design enroll four group participant US South Africa , successive group receive increase dos vaccine , later amend enroll two group . Twelve US participant ( US Group 1 ) randomize receive either vaccine placebo . After review initial safety data group , 12 South African participant ( SA Group 1 ) randomize receive vaccine dose US Group 1 placebo , 12 US participant ( US Group 2 ) randomize receive next high vaccine dose placebo . Review safety data SA Group 1 US Group 2 use inform decision begin enrollment SA Group 2 . Participants nine study visit 12 month . Study visit include clinical evaluation , urine blood test , HIV test . After injection , participant ask record temperature symptom day 7 day report clinic staff .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria HIV negative Willing receive HIV test result Good general health Acceptable method contraception female reproductive potential Hepatitis B surface antigen negative Antihepatitis C virus antibody ( antiHCV ) negative negative HCV PCR antiHCV positive Access participate site available followup 12 month study Exclusion Criteria HIV vaccine placebos prior HIV vaccine trial Measurable antiVEE antibody High risk HIV infection accord HVTN Risk Criteria Immunosuppressive medication within 168 day prior first study vaccine administration Blood product within 120 day prior first study vaccine administration Immunoglobulin within 60 day prior first study vaccine administration Live attenuate vaccine within 30 day prior first study vaccine administration Investigational research agent within 30 day prior first study vaccine administration Subunit kill vaccine within 14 day prior first study vaccine administration Current tuberculosis prophylaxis therapy Active syphilis Serious adverse reaction vaccine . A person adverse reaction pertussis vaccine child exclude . Autoimmune disease immunodeficiency Unstable asthma Type 1 Type 2 Diabetes Mellitus Thyroid disease require treatment Serious angioedema within past 3 year Uncontrolled hypertension Bleeding disorder Malignancy unless surgically remove , opinion investigator , likely recur study period Seizure disorder require medication within past 3 year Asplenia Mental illness would interfere compliance protocol Other condition , judgement investigator , would interfere study Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>Gene Products , gag</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Dose-Response Relationship , Immunologic</keyword>
	<keyword>Injections , Subcutaneous</keyword>
</DOC>